Kendall is an analytical chemist with many years of mass spectrometry experience. She joined InduPro for the exciting opportunity to apply innovative proteomics approaches to early drug discovery and translational research. 

Kendall earned her B.S in biochemistry at Villanova University. As a Massachusetts native, she returned to Cambridge to gain valuable industry experience working as a research associate in metabolomics before completing her PhD in chemistry at Northeastern University in the lab of Alexander Ivanov. During her PhD, Kendall worked on enhancing proteomic sensitivity from limited sample material down to the level of single cells.  

Outside of work she enjoys golfing, cooking, and spending time with friends and family. 

As a lifelong resident of Seattle, Karla’s career in HR has spanned across a variety of industry leading organizations such as Technology & Software; Consumer Products & Retail; Healthcare; Banking & Finance; Food & Beverage; Manufacturing; Legal Services; and Music/Entertainment. Her experience also encompasses the full range of company size from start up to mid sized to large global organizations where she contributes as a key strategic business partner for both C suite and senior leadership to develop and drive business specific talent activation plans to enable higher profit margins and market share growth. In addition to the HR Business partner leadership role, she has led and developed HR teams focused in the areas of Talent Acquisition, Total Rewards, Employee Relations, Performance Management and Leadership development. Karla has consistently been recognized by her clients for having a deep understanding of business drivers and creating talent development strategies that directly link service delivery to strategic priorities and culture by attracting top-tier talent, developing leaders, cultural transformation and building a resilient workforce. 

What initially drew Karla to InduPro was their focus on improving healthcare outcomes via their mission to save patients’ lives through innovating drug design that provides the ability to address biology and therapeutic targets in new ways. 

Outside of work, Karla can be found living her best empty nester life with her husband of over 25 years, cheering on her two favorite football teams (Seahawks and EWU Eagles); snowmobiling; cooking; wine tasting; travelling and gardening. 

Anika joined InduPro in June 2022 and is focused on applying her expertise in protein purification and structural biology to help the team develop new platforms. She enjoys working at InduPro both because of the exciting work but also because of her supportive and creative colleagues.

Anika grew up in the Pacific Northwest and got her BA in Chemistry from Pomona College. She completed her PhD in Biochemistry at the University of Washington where she used cryo-electron microscopy to determine the structures of protein complexes and understand how they relate to human disease.

When not working, Anika enjoys playing ultimate frisbee, hiking, and baking desserts.

Zachary worked for a number of small Seattle biotech start-ups in various Process Development roles before joining Indupro. He joined the Protein Sciences group to produce biologics from multiple mammalian cell platforms for downstream purification and analysis. Additional focus involves process optimization and adaptation of protocols to high-throughput, automated platforms.

Outside of the lab he enjoys exploring new environments in Washington with his family and dog Star.

Amanda joined InduPro in June 2022 with the selling point that every day would be different and filled with new challenges – and that promise has stayed true. As the Office Manager, she keeps all the behind-the-scenes processes running efficiently so that those in the lab can stay on task. Everyday looks different, and that’s her favorite part of the job!

Hailing from Detroit, Michigan, Amanda moved to Seattle in 2019 to continue her work in the non-profit sector. Coming with experience of working in 15 different countries and 20 states leading humanitarian efforts, Amanda loves people and solving problems. After 8 years, the transition into biotech has been a rewarding and exciting one thanks to her coworkers who keep the bigger mission in mind and leadership that makes sure everyone has a seat at the table.

Outside of work, Amanda reads a few books a week, enjoys a good brewery, camps as often as she can with her husband and two pups, and is doing her best to fill up her passport with stamps and stories.

Noah heads up the proteomics team at InduPro. He earned his PhD at the University of California, San Francisco studying protein kinase signaling in budding yeast in the laboratory of Erin O’Shea. His interest in protein phosphorylation led him to a post-doc with Steve Gygi at Harvard Medical School. In the Gygi Lab, he developed methods for increasing the through-put and depth of analysis of large-scale quantitative proteomics and phosphoproteomics. He applied these methods to study cell-cycle regulation, the response to rapamycin, and the proteomic consequences of aneuploidy. Before joining InduPro, Noah continued working to refine the proteomic toolbox in his lab at Weill Cornell Medical College. Outside of work, he enjoys skiing, fishing, and crossword puzzles.

Payam is a scientist formally trained in chemical and biological engineering, with passions for synthetic biology and cell signaling. During his PhD, he developed optogenetic tools and live-cell biosensors to study signaling dynamics of receptor tyrosine kinases and their downstream pathways. At InduPro, he is using his expertise to characterize inducers of protein proximity through high-throughput screening approaches.

Outside of work, Payam enjoys cooking, bike rides around Seattle, and adventures in the nearby mountains.

Carol eagerly joined InduPro in April of 2022 as a Sr. Associate Scientist on the InduPro Molecular Discovery team. She is an enthusiastic biochemist and molecular biologist who loves taking genes from concept to protein ready for enabling InduPro science to ultimately help patients with unmet medical need.

Carol received a Master’s of Science degree in Biochemistry and Molecular Biology from Michigan State University where she studied mitochondrial DNA polymerase replication as both and undergraduate and graduate student. Carol fled the gloomy Midwest winters for the sunny eternal- spring shores of San Diego joining The Scripps Research Institute working as part of the Joint Center for Structural Genomics NIH Protein Structure Initiative.

Before joining the InduPro team she worked at the Novartis Institute for Biomedical Research San Diego (formerly GNF) in Antibody Discovery developing antibody cloning and expression methods in support of various early drug discovery projects.

Outside of work, she is reembracing the seasons in the PNW, enjoying adventures with her husband, pizza making, cooking/baking, photography, hiking, and traveling. A favorite part of cooking and baking is challenging herself to use what she has on hand in the end creating unusual, sweet, or savory flavor combinations.

Niyi Fadeyi is InduPro’s Vice President of Chemical Sciences leading discovery chemistry and chemical biology efforts for early target discovery and platform chemistry technologies.

Prior to InduPro, Niyi was a founding member of the Merck Exploratory Science Center and served as the Head of Molecular Discovery group and co-lead of the cellular chemistry team. In this capacity, he led a group working at the interface of chemistry and biology towards creating robust and innovative drug pipelines, delivering novel therapeutic targets across multiple therapeutic areas and developing drug discovery platform technologies. He co-invented light powered protein microenvironment mapping technology for profiling protein-neighborhoods in a high-resolution manner.

Before Merck, Niyi was at Pfizer as a Principal Scientist within the Inflammation & Immunology/Rare Diseases division (medicinal chemistry and chemical biology). In that capacity, he contributed to medicinal chemistry/chemical biology programs and led chemistry efforts across a broad range of target classes, some of which have advanced into the clinical phase.

Niyi was a UNCF/Merck postdoctoral fellow at Department of Chemistry and Chemical Biology, Harvard University in the lab of Prof. Matthew Shair. In 2011, he obtained his doctoral degree at Vanderbilt University, under the mentorship of Prof. Craig Lindsley. Niyi holds a B.S. in chemistry from Obafemi Awolowo University, Nigeria and a M.Sc. from the Tennessee State University. Niyi serves on the advisory board of ACS Journal of Medicinal Chemistry and is an Early Career Board member of ACS Medicinal Chemistry Letters.

He is a co-founder of the STEM Hub for Industry Networking and Exchange (S.H.I.N.E.) program, a non-profit mentoring program for underrepresented STEM students.

Robert is responsible for the Single B Cell Antibody Discovery pipeline at InduPro. He is passionate about leveraging biologics to improve upon the quality of life for patients, regardless of their disease. This drive to help people was realized during an internship at Amgen British Columbia, and evolved into stints at the National Research Council of Canada, Takeda California, and Zymeworks. Robert graduated from Simon Fraser University (BSc 2009) and the University of Guelph (MSc 2013).

When Robert is not reading the latest articles in “mAbs”, he is cheering on his Vancouver Canucks or enjoying the PNW with his young family.

Jim eagerly embraced the opportunity to join the founding team of InduPro. The immense potential was clear, and the nascent leadership team created a fantastic synergy.

He brings a proven track record of success on executive leadership teams building and supporting new company infrastructure previously with AlivaMab Discovery Services, Sevion Therapeutics, and Fabrus by segregating administrative distractions from the research teams allowing them to focus on value creation. Prior to moving solely into operations leadership, Jim also concurrently held roles managing lab automation systems, cell line development, and bioprocessing. The insights and experiences gained training and working as a scientist contribute to his effectiveness as an operations executive.

Jim received his PhD in molecular biology from The Scripps Research Institute and a BA from UC Berkeley. This followed diverse career transitions as a qualified nuclear-trained engineering mechanic in the US Navy to industrial chemical plant maintenance mechanic and cellar/vineyard hand with a winery in the Santa Cruz mountains.

Outside of InduPro, Jim strives to become a certified bon vivant enjoying baking and cooking, fermenting anything, and sharing it all with his partner, three kids, and friends over colorful stories he’s still collecting in a life well-lived.

Tsadik is an immunologist with a strong desire for developing therapeutics to unmet medical needs. He is applying Indupro’s unique platform to explore bispecific antibodies in enhancing immunogenicity.  

He grew up in Eritrea and moved to the US for graduate school. During his PhD, Tsadik studied the metabolic crosstalk between cancer cells and T cells in the setting of adoptive T cell therapy (ACT). He then joined Fred Hutch cancer research center as a post-doc, where he worked on cell therapy targeting minor antigens. After that, Tsadik joined Gilead sciences where he worked on small molecule inhibitors and tumor immunogenicity. He maintains strong interest in exploring immune-metabolism and the potential for novel targets to reprogram T cell metabolic fitness.  

Outside work, Tsadik enjoys swimming, cooking Eritrean/Ethiopian food, and visiting nearby nature sites.   

Pam Holland is InduPro’s Sr. Vice President of Biology, and will oversee pipeline development and contribute to the execution of InduPro’s strategic objectives.

Prior to joining InduPro, Pam was Sr. Vice President of Research at Alpine Immune Sciences, where she was responsible for overseeing the development and advancement of internal research programs and managing external pre-clinical collaborations. These included protein-based candidate therapeutics derived from an internal directed-evolution platform utilizing novel protein engineering strategies, aimed at both oncology and autoimmune/inflammation therapeutic areas.

Prior to joining Alpine, Pam served as Vice President, Cancer Biology at Surface Oncology in Cambridge MA, overseeing biology and immunology research. During her tenure she played key roles in developing the Surface pipeline, driving multiple pre-clinical programs into Phase 1, as well as the establishment of an early strategic partnership with Novartis and later with GSK. Prior to joining Surface, Pam held roles of increasing responsibility in oncology research at Amgen, working extensively on TNF-receptor superfamily members including death-receptor agonists. Members of her team were instrumental in the development of multiple discovery programs for cancer immunotherapy.

Pam received her bachelor’s degree from the University of California, San Diego and her PhD from the University of Washington/Fred Hutchinson Cancer Research Center in the lab of Dr. Jonathan Cooper. She also held a post-doctoral position at Immunex prior to the Amgen acquisition. Before graduate school, Pam worked at Cetus Corporation in Emeryville, CA where she was a key contributor to the development of TaqMan™. She is a co-inventor on all TaqMan patents and was the lead author on the first publication describing TaqMan in 1991.

Michael Hornsby is InduPro’s Director of Molecular Discovery and leads the antibody discovery, assay development, screening, and automation activities at the company.

Prior to joining InduPro, Michael was an Associate Director at Bristol Myers Squibb overseeing the Antibody Platform Technologies group and was responsible for developing high throughput automation tools for the generation and validation of therapeutic antibody molecules. He led efforts to develop antibodies from Hybridoma and Single B-Cell screening modalities and to lead the laboratory automation for the Redwood City BMS site.

Prior to his role at BMS, Michael led the UCSF Antibiome in the laboratory of Dr. Jim Wells. He also co-led the Recombinant Antibody Network (RAN), a consortium consisting of the laboratories of Dr. Jim Wells (University of California, San Francisco), Dr. Anthony Kossiakoff (University of Chicago), and Dr. Sachdev Sidhu (University of Toronto). The UCSF Antibiome and RAN developed phage derived antibody discovery pipeline for the generation of therapeutic antibody molecules at a proteome-wide scale.

Prior to his role with the UCSF Antibiome and the RAN, he was at the Genomics Institute of the Novartis Research Foundation (GNF). There he participated in the development of research and technology platforms focused on protein structure and function and high throughput technologies.

Michael received his Ph.D. in Microbiology from the University of California, Davis and his B.S. in Microbiology from Oregon State University.

Dillon joined InduPro as the Accounting Manager in May 2023. He attended Northeastern University and began his career in public accounting at KPMG Boston before moving out to the west coast in 2017.  

Prior to joining InduPro, Dillon spent several years working on the finance and accounting team at Impel Pharmaceuticals in Seattle, primarily supporting clinical development and other R&D related activities. This experience solidified a passion for working in the life science industry and has given him a depth of knowledge for his role at InduPro.  

In his free time Dillon enjoys trail running, backcountry skiing and exploring the Pacific Northwest.  

Scott Lesley is InduPro’s Chief Scientific Officer leading all platform and drug discovery functions at the Company.

Prior to joining InduPro, Scott was Vice President of Discovery Biologics at Merck and was responsible for a broad preclinical pipeline of molecules across all therapeutic areas within Merck. This included diverse modalities such as multifunctional antibodies and engineered proteins, ADCs, oncolytic viruses and cell therapies.

Prior to his role at Merck, Scott was at Novartis. He joined the Genomics Institute of the Novartis Research Foundation (GNF) at its inception. There, he established research and technology platforms in biotherapeutics, protein engineering, protein structure and function, and high-throughput technologies. In his role as the Executive Director of Biotherapeutics and Biotechnology he oversaw scientists and engineers responsible for biotherapeutics discovery and optimization, structural biology, HTS, functional genomics, automation and engineering.

Scott also maintained a faculty appointment at The Scripps Research Institute from 2005-2016 and led an independent research lab as Co-PI of the Joint Center for Structural Genomics (JCSG) studying protein structure and function with an emphasis on host/microbe interactions. The JCSG was responsible for over 1600 novel protein structures.

Prior to joining GNF, he was a Sr. Research Scientist at Promega Corporation and has had postdoctoral positions at the University of California, Berkeley, and the University of Wisconsin, Madison. Scott received his Ph.D. in Molecular Biology from the University of Wisconsin and a B.S. in Microbiology from the University of Illinois. He has over 200 publications to date and has contributed to novel therapeutic targets, therapeutic modalities, small molecule and biotherapeutic clinical candidates and registered drugs, as well as developing platform technologies in HTS and other automation for drug discovery.

At InduPro, Chris May is focused on mapping cell surface protein microenvironments in order to identify proximal proteins and discover novel therapeutics through protein pairing.

During his PhD, Chris worked on regulation of gene expression by proteins of the inner nuclear membrane. As a postdoc, he investigated the roles of cell penetrating antibodies in autoimmune disease and their potential use as cancer therapeutics.

Outside of work, Chris enjoys craft projects, cooking and gardening.

Clare is a cancer biologist with substantial experience in oncology therapeutic development. She joined InduPro because she is passionate about translating laboratory discoveries into improved health outcomes, and she is proud to be applying InduPro’s unique platforms to unmet clinical needs in oncology.

Clare grew up in the Chicago area and then received her B.A. in Biology and French Language and Literature from Williams College. She did her PhD in the Biological and Biomedical Sciences program at Harvard University. At Harvard, she used hypothesis-based approaches to develop new combination therapies for malignant peripheral nerve sheath tumors. During her PhD, she also earned an engraved mug at Penguin Pizza. Clare then did her postdoctoral fellowship at Dana-Farber Cancer Institute and the Broad Institute where she focused on discovering and characterizing novel therapeutic targets in pediatric cancers using functional genomic screening.

Outside of lab, she enjoys knitting, trying to keep her lemon tree alive, and winning fantasy football championships.

Jason Misurelli is a Senior Research Associate on the Molecular Discovery team, where his primary role involves generating lipid nanoparticle (LNP) immunizations for targets of interest. His previous academic research focused on aspects of immune signaling and metabolism within the tumor microenvironment (TME).

Jason earned his B.S. and M.S. in biology from Northern Illinois University. His master’s thesis examined the relationship between hypoxia and glutamine transport in hepatocellular carcinoma.

In his free time, Jason enjoys photography, cooking, and making coffee in complicated ways.

Christie grew up as a “Navy brat” and lived in Japan for most of her childhood. After moving back to the U.S., her family settled down in Oak Harbor, Whidbey Island, where she enjoyed going to the drive-in movies with friends and never grew tired of passing through the scenic Deception Pass. Christie went to UW in Seattle where she received her B.S. in Cellular, Molecular, and Developmental Biology. From her undergraduate research experience, and working as a Research Technician at the Fred Hutch, Christie developed a passion and curiosity for immunology. She completed her PhD studies at UC Irvine, where she investigated how manipulating the global N-glycosylation levels on the surface of immune cells can alter their function and how this had implications in various immune disorders. After graduate school, Christie explored an interest in science policy and joined Catalyst Healthcare Consulting where she gained exposure and experience as a consultant in FDA regulatory affairs. While she enjoyed learning about, and advising biopharma and biotech clients, on FDA activities, Christie soon realized she missed the bench and wanted to be a part of research discoveries that would lead to better therapies for patients. She then joined Neoleukin Therapeutics’ Immunology team, where she began building a foundation of industry-focused research skills. Christie joined the Immunology team at InduPro in July 2022, and is excited about learning how to best leverage inherent and induced proximity of cell surface proteins to manipulate immune cell functions. At InduPro, there are many opportunities for career growth and Christie is looking forward to gaining more experience in cross-functional collaborations, management, and strategic development.

Outside of work, Christie enjoys playing video and board games, and spending time with her husband, “tripawd” dog, and two cats. She always looks forward to the beautiful Seattle summers so she can paddleboard and go fishing on the lakes with friends.

Rob Oslund is InduPro’s Vice President of Platform Technology leading chemical biology and proximity labeling platform technology functions at the Company.

Prior to joining InduPro, Rob was a founding member of the Merck Exploratory Science Center co-leading a cellular chemistry team focused on developing novel platform technologies to enable therapeutic development. He co-invented photocatalytic-based proximity labeling and led efforts to profile surface protein environments and explore cell-cell interaction biology. Also while at Merck, Rob developed novel covalent labeling technologies for target identification and was involved in multiple modality agnostic drug discovery programs. Rob is a co-founder of the STEM Hub for Industry Networking and Exchange (S.H.I.N.E.) program for underrepresented STEM students with over 400 mentee/mentor pairs participating across 25 biotech/pharma companies.

Prior to Merck, Rob was a peptide chemist and biochemist at Neon Therapeutics (now BioNTech) developing high throughput peptide synthesis platforms and proteomic workflows to investigate HLA peptide ligandomes for cancer vaccine development.

Rob did his postdoc in the lab of Tom Muir at Princeton University where he developed a pan-specific antibody to phosphorylated histidine and applied this to biological systems to investigate the role of bisphosphoglycerate mutase in serine pathway flux. Rob earned his PhD from the University of Washington in Seattle with Professor Mike Gelb where he studied phospholipase enzymes through design and synthesis of selective phospholipase small molecule inhibitors. Rob received his B.S. in Chemistry from Southern Utah University in Cedar City, Utah. He is originally from Henderson, NV.

Anna de Regt is an antibody engineer at InduPro; she works on transforming antibody sequences into therapeutic candidates. Before joining InduPro, Anna was at Neoleukin Therapeutics, seeking to improve the therapeutic window of de novo designed cytokine drugs by targeting them specifically to the tumor microenvironment. Prior to that, she was in the protein engineering group at Seagen, where she developed cytotoxic antibody-drug conjugates with novel protein structures and functions. She is excited to be building on these experiences and bringing elevated bispecific antibodies to patients with InduPro. 

Anna grew up in the Pacific Northwest but left to study engineering at Swarthmore and earn her PhD in biochemistry at MIT. She then returned to Washington to do her postdoc at Fred Hutch and climb in the Cascades. These days, when not working with antibodies, she can be found running trails in the mountains and spending time with her family. 

Suzie Ruskin is a research associate II on the Molecular Discovery team bringing 6 years of scientific research expertise, mostly in the field of immunology. In her role she is responsible for helping continue our high throughput molecular biology platform.

Prior to joining InduPro, Suzie was a research technician at Fred Hutchinson Cancer Research Center in the Greenberg Lab for 6 years. During that time, her studies focused on engineering adoptive T cell therapy to integrate Fas ligand-mediated death signaling in ovarian cancer. Suzie was responsible for troubleshooting and optimizing experimental methods, as well as the subsequent data analysis, which primarily focused on flow cytometry of engineered cells and mouse model studies.

Suzie received her BS in Physiology with a minor in eco-theology in June 2020. In her free time she loves hiking in the PNW and spending time with her family and on the family cattle ranch in Arizona!

Aniruddh is a Research Associate II in the Immunology team at InduPro. He works on studying the interactions of InduPro’s drug candidates with immune cells and understand how these interactions are controlled and can be modulated. Prior to joining InduPro, Aniruddh used to work at Sana Biotechnology where he worked on developing in-vivo CAR-T cell therapy and before that, he used to study Duchenne Muscular Dystrophy using hiPSCs during his undergrad coursework at the University of Washington.

Outside of work, Aniruddh enjoys climbing, hiking and paddle boarding in Lake Union.

Ben joined InduPro in 2022 and is responsible for the purification, modification and characterization of InduPro’s wide-ranging biologics platforms. He’s a native to the Northwest, receiving his BS at the University of Washington in 2005. He previously worked at Emergent Biosolutions in CMC developing biologic processes and as a PiP generating clinical drugs in GMP plants. He then moved to Silverback Therapeutics where he was in protein discovery with a focus on screening proteins from hybridoma and progressing them into drug candidate stage.

When he’s not in the lab, he can be found with his family in the mountains skiing, hiking and foraging or on the sound fishing the waters from his kayak.

Lauren is an immunologist testing multi-specific antibodies to modulate immune cell activation in disease. Lauren exploits InduPro technology to characterize the protein landscape of immune cells. Prior to joining InduPro, Lauren studied mechanisms of immune activation in response to parasitic and allergic disease. She completed her PhD in Immunology at the University of Edinburgh, UK, and did postdoctoral work at the University of Manchester, UK, Cornell University, and University of Washington.

Lauren maintains a soft spot for multicellular parasitic beasties but is also passionate about harnessing the therapeutic potential of immune cells. Outside of science, Lauren enjoys hiking, gardening, exploring the PNW, and cheering on the Seattle Sounders.

Lydia followed the biomedical engineering research track at Tufts University. There she received hands on experience in multiple labs, honing her interest on the groundbreaking world of biomedical sensing. She even won the senior capstone award for her outstanding research and communication abilities. Once graduated, she explored translational research at Massachusetts General Hospital, leading a team to design a transesophageal hemodynamic probe. Deciding that objects on the millimeter scale were too large, Lydia joined InduPro to work with the microscopic. She hopes to begin her PhD in fall of 2024.

Lydia loves board games, exploring, going to the gym with friends, cooking, and crafts. She struggles to pick just one art form, but has recently taken an interest in embroidery. However, her favorite activity of all is snuggling her lovely cat Sadie.

Niyi Fadeyi is InduPro’s Vice President of Chemical Sciences leading discovery chemistry and chemical biology efforts for early target discovery and platform chemistry technologies.

Prior to InduPro, Niyi was a founding member of the Merck Exploratory Science Center and served as the Head of Molecular Discovery group and co-lead of the cellular chemistry team. In this capacity, he led a group working at the interface of chemistry and biology towards creating robust and innovative drug pipelines, delivering novel therapeutic targets across multiple therapeutic areas and developing drug discovery platform technologies. He co-invented light powered protein microenvironment mapping technology for profiling protein-neighborhoods in a high-resolution manner.

Before Merck, Niyi was at Pfizer as a Principal Scientist within the Inflammation & Immunology/Rare Diseases division (medicinal chemistry and chemical biology). In that capacity, he contributed to medicinal chemistry/chemical biology programs and led chemistry efforts across a broad range of target classes, some of which have advanced into the clinical phase.

Niyi was a UNCF/Merck postdoctoral fellow at Department of Chemistry and Chemical Biology, Harvard University in the lab of Prof. Matthew Shair. In 2011, he obtained his doctoral degree at Vanderbilt University, under the mentorship of Prof. Craig Lindsley. Niyi holds a B.S. in chemistry from Obafemi Awolowo University, Nigeria and a M.Sc. from the Tennessee State University. Niyi serves on the advisory board of ACS Journal of Medicinal Chemistry and is an Early Career Board member of ACS Medicinal Chemistry Letters.

He is a co-founder of the STEM Hub for Industry Networking and Exchange (S.H.I.N.E.) program, a non-profit mentoring program for underrepresented STEM students.

Jim eagerly embraced the opportunity to join the founding team of InduPro. The immense potential was clear, and the nascent leadership team created a fantastic synergy.

He brings a proven track record of success on executive leadership teams building and supporting new company infrastructure previously with AlivaMab Discovery Services, Sevion Therapeutics, and Fabrus by segregating administrative distractions from the research teams allowing them to focus on value creation. Prior to moving solely into operations leadership, Jim also concurrently held roles managing lab automation systems, cell line development, and bioprocessing. The insights and experiences gained training and working as a scientist contribute to his effectiveness as an operations executive.

Jim received his PhD in molecular biology from The Scripps Research Institute and a BA from UC Berkeley. This followed diverse career transitions as a qualified nuclear-trained engineering mechanic in the US Navy to industrial chemical plant maintenance mechanic and cellar/vineyard hand with a winery in the Santa Cruz mountains.

Outside of InduPro, Jim strives to become a certified bon vivant enjoying baking and cooking, fermenting anything, and sharing it all with his partner, three kids, and friends over colorful stories he’s still collecting in a life well-lived.

Pam Holland is InduPro’s Sr. Vice President of Biology, and will oversee pipeline development and contribute to the execution of InduPro’s strategic objectives.

Prior to joining InduPro, Pam was Sr. Vice President of Research at Alpine Immune Sciences, where she was responsible for overseeing the development and advancement of internal research programs and managing external pre-clinical collaborations. These included protein-based candidate therapeutics derived from an internal directed-evolution platform utilizing novel protein engineering strategies, aimed at both oncology and autoimmune/inflammation therapeutic areas.

Prior to joining Alpine, Pam served as Vice President, Cancer Biology at Surface Oncology in Cambridge MA, overseeing biology and immunology research. During her tenure she played key roles in developing the Surface pipeline, driving multiple pre-clinical programs into Phase 1, as well as the establishment of an early strategic partnership with Novartis and later with GSK. Prior to joining Surface, Pam held roles of increasing responsibility in oncology research at Amgen, working extensively on TNF-receptor superfamily members including death-receptor agonists. Members of her team were instrumental in the development of multiple discovery programs for cancer immunotherapy.

Pam received her bachelor’s degree from the University of California, San Diego and her PhD from the University of Washington/Fred Hutchinson Cancer Research Center in the lab of Dr. Jonathan Cooper. She also held a post-doctoral position at Immunex prior to the Amgen acquisition. Before graduate school, Pam worked at Cetus Corporation in Emeryville, CA where she was a key contributor to the development of TaqMan™. She is a co-inventor on all TaqMan patents and was the lead author on the first publication describing TaqMan in 1991.

Michael Hornsby is InduPro’s Director of Molecular Discovery and leads the antibody discovery, assay development, screening, and automation activities at the company.

Prior to joining InduPro, Michael was an Associate Director at Bristol Myers Squibb overseeing the Antibody Platform Technologies group and was responsible for developing high throughput automation tools for the generation and validation of therapeutic antibody molecules. He led efforts to develop antibodies from Hybridoma and Single B-Cell screening modalities and to lead the laboratory automation for the Redwood City BMS site.

Prior to his role at BMS, Michael led the UCSF Antibiome in the laboratory of Dr. Jim Wells. He also co-led the Recombinant Antibody Network (RAN), a consortium consisting of the laboratories of Dr. Jim Wells (University of California, San Francisco), Dr. Anthony Kossiakoff (University of Chicago), and Dr. Sachdev Sidhu (University of Toronto). The UCSF Antibiome and RAN developed phage derived antibody discovery pipeline for the generation of therapeutic antibody molecules at a proteome-wide scale.

Prior to his role with the UCSF Antibiome and the RAN, he was at the Genomics Institute of the Novartis Research Foundation (GNF). There he participated in the development of research and technology platforms focused on protein structure and function and high throughput technologies.

Michael received his Ph.D. in Microbiology from the University of California, Davis and his B.S. in Microbiology from Oregon State University.

Scott Lesley is InduPro’s Chief Scientific Officer leading all platform and drug discovery functions at the Company.

Prior to joining InduPro, Scott was Vice President of Discovery Biologics at Merck and was responsible for a broad preclinical pipeline of molecules across all therapeutic areas within Merck. This included diverse modalities such as multifunctional antibodies and engineered proteins, ADCs, oncolytic viruses and cell therapies.

Prior to his role at Merck, Scott was at Novartis. He joined the Genomics Institute of the Novartis Research Foundation (GNF) at its inception. There, he established research and technology platforms in biotherapeutics, protein engineering, protein structure and function, and high-throughput technologies. In his role as the Executive Director of Biotherapeutics and Biotechnology he oversaw scientists and engineers responsible for biotherapeutics discovery and optimization, structural biology, HTS, functional genomics, automation and engineering.

Scott also maintained a faculty appointment at The Scripps Research Institute from 2005-2016 and led an independent research lab as Co-PI of the Joint Center for Structural Genomics (JCSG) studying protein structure and function with an emphasis on host/microbe interactions. The JCSG was responsible for over 1600 novel protein structures.

Prior to joining GNF, he was a Sr. Research Scientist at Promega Corporation and has had postdoctoral positions at the University of California, Berkeley, and the University of Wisconsin, Madison. Scott received his Ph.D. in Molecular Biology from the University of Wisconsin and a B.S. in Microbiology from the University of Illinois. He has over 200 publications to date and has contributed to novel therapeutic targets, therapeutic modalities, small molecule and biotherapeutic clinical candidates and registered drugs, as well as developing platform technologies in HTS and other automation for drug discovery.

Rob Oslund is InduPro’s Vice President of Platform Technology leading chemical biology and proximity labeling platform technology functions at the Company.

Prior to joining InduPro, Rob was a founding member of the Merck Exploratory Science Center co-leading a cellular chemistry team focused on developing novel platform technologies to enable therapeutic development. He co-invented photocatalytic-based proximity labeling and led efforts to profile surface protein environments and explore cell-cell interaction biology. Also while at Merck, Rob developed novel covalent labeling technologies for target identification and was involved in multiple modality agnostic drug discovery programs. Rob is a co-founder of the STEM Hub for Industry Networking and Exchange (S.H.I.N.E.) program for underrepresented STEM students with over 400 mentee/mentor pairs participating across 25 biotech/pharma companies.

Prior to Merck, Rob was a peptide chemist and biochemist at Neon Therapeutics (now BioNTech) developing high throughput peptide synthesis platforms and proteomic workflows to investigate HLA peptide ligandomes for cancer vaccine development.

Rob did his postdoc in the lab of Tom Muir at Princeton University where he developed a pan-specific antibody to phosphorylated histidine and applied this to biological systems to investigate the role of bisphosphoglycerate mutase in serine pathway flux. Rob earned his PhD from the University of Washington in Seattle with Professor Mike Gelb where he studied phospholipase enzymes through design and synthesis of selective phospholipase small molecule inhibitors. Rob received his B.S. in Chemistry from Southern Utah University in Cedar City, Utah. He is originally from Henderson, NV.

Professor of Molecular and Cellular Physiology and Structural Biology, Stanford School of Medicine

Research →